Matching articles for "February 23"
Issue 1306 · February 23, 2009
PPI Interactions with Clopidogrel Revisted

Current guidelines recommend use of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal bleeding in patients taking clopidogrel (Plavix) with aspirin. A recent issue of The Medical Letter…

Med Lett Drugs Ther. 2009 Feb 23; 51(1306):13-4
Current guidelines recommend use of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal bleeding in patients taking clopidogrel (Plavix) with aspirin. A recent issue of The Medical Letter considered whether omeprazole ( Prilosec , and others) or other PPIs could interfere with the antiplatelet effect of clopidogrel. The conclusion was that patients taking both drugs should probably continue to do so until more data became available. Several new publications require reconsideration of that recommendation.
Issue 1306 · February 23, 2009
Conjugated Estrogens (Premarin) Vaginal Cream

An old conjugated estrogens vaginal cream ( Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy…

Med Lett Drugs Ther. 2009 Feb 23; 51(1306):14-5
An old conjugated estrogens vaginal cream ( Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Synthetic conjugated estrogens A vaginal cream (Barr) has also been approved for this indication, but has not yet been marketed.
Issue 1306 · February 23, 2009
Screening for Oral Cancer

The incidence of oral cancer appears to be increasing, especially in younger patients. Risk factors include use of tobacco and alcohol, and exposure to human papillomavirus. ViziLite Plus (Zila…

Med Lett Drugs Ther. 2009 Feb 23; 51(1306):15-6
The incidence of oral cancer appears to be increasing, especially in younger patients. Risk factors include use of tobacco and alcohol, and exposure to human papillomavirus. ViziLite Plus (Zila Pharmaceuticals) is a combination device that uses fluorescent light and toluidine blue tissue staining to help dentists identify abnormal changes in the mucous membranes of the oral cavity. Originally developed for detecting abnormal growths on the uterine cervix, in 2001 it received FDA clearance for "identification, evaluation, and monitoring of oral mucosal abnormalities in a patient population at increased risk for oral cancer." The toluidine blue marking system was cleared for inclusion in 2005.
Issue 1306 · February 23, 2009 Free
In Brief: Cardiac Risks of Antipsychotic Drugs

A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death.…

Med Lett Drugs Ther. 2009 Feb 23; 51(1306):13
A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death. Typical antipsychotics have long been associated with this risk. In this study, however, the incidence of sudden cardiac death was similar with typical and atypical antipsychotics: about 1 in 340 person-years among the patients who took typical (first generation) antipsychotics such as haloperidol ( Haldol , and others) and 1 in 360 personyears among those who took atypical (second-generation) drugs such as olanzapine (Zyprexa) , compared to 1 in 700 patient-years among otherwise similar nonusers of antipsychotic drugs. The risk increased with the dose of the drug and also with the age of the patient; the authors state that they did not include patients younger than 30 because sudden cardiac death is very rare in the younger age group. 1 Second-generation drugs are less likely than first generation drugs to cause extrapyramidal symptoms, tardive dyskinesia and neuroleptic malignant syndrome, but more likely to cause weight gain and other metabolic abnormalities. 2 Aripiprazole (Abilify) 3 is least likely to prolong the QT interval, which is one of the mechanisms that could be responsible for the small increase in the absolute risk of sudden death among patients who take antipsychotic drugs. In a patient with a good indication for its use, the consequences of not taking an antipsychotic drug may be greater than the risks of taking one. 1. WA Ray et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225. 2. Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35. 3. Second-generation antipsychotics — aripiprazole revisited. Med Lett Drugs Ther 2005; 47:81. Download: U.S. English